Podcasts about mounjaro

No Dia Mundial da Obesidade, Flávio Trombino reflete sobre o impacto de medicamentos como Mounjaro e Ozempic na gastronomia. See omnystudio.com/listener for privacy information.

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound are reshaping the treatment of obesity around the world. But even when these medicines are judged “cost-effective”, access often depends on who can afford to pay. In the second episode of our Business Daily series on the global weight-loss economy, Sam Fenwick examines how different countries are funding — or rationing — access to these high-priced injections. In England, the state's National Health System says the drugs offer good value for money, and yet rollout is being phased in slowly because of cost and capacity pressures. In the United Arab Emirates, most patients rely on private insurance or pay out of their own pockets. And in India, where obesity is rising fast, affordability remains a major barrier, although lower-cost generics may soon change that. If these medicines can prevent diabetes, heart attacks and strokes, they might save health systems money in the long run. But right now, governments, insurers and patients are grappling with the same question: Can we afford the weight-loss revolution?Produced and presented by Sam FenwickIf you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukBusiness Daily is the home of in-depth audio journalism devoted to the world of money and work. From small start-up stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs. These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Photo: A man gets his waist measured. Credit: Getty Images)

Une étude anglaise publiée ces derniers jours montre que les traitements injectables anti-obésité (Wegovy et Mounjaro) permettent bien de perdre beaucoup de poids... Mais pour peu de temps ! Seulement 18 mois après la fin du traitement, la plupart des patients avaient repris tout le poids perdu. En cette veille de journée mondiale contre l'obésité, notre spécialiste santé Agathe Landais fait le point sur ces traitements qui promettent une perte de poids rapide, et qui font fureur en Europe et aux Etats-Unis. Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed avec Agathe Landais du 03 mars 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick examines the real cost of obesity drugs in the U.S. healthcare system.How much do GLP-1 medications like Ozempic, Wegovy, Zepbound and Mounjaro actually cost? Are they cost-effective in the long term? And can insurers and employers afford to provide them to millions of Americans living with obesity?If you'd like to get in touch with the team, our email address is businessdaily@bbc.co.ukProduced and presented by Sam Fenwick.Business Daily is the home of in-depth audio journalism devoted to the world of money and work. From small startup stories to big corporate takeovers, global economic shifts to trends in technology, we look at the key figures, ideas and events shaping business.Each episode is a 17-minute deep dive into a single topic, featuring expert analysis and the people at the heart of the story.Recent episodes explore the weight-loss drug revolution, the growth in AI, the cost of living, why bond markets are so powerful, China's property bubble, and Gen Z's experience of the current job market.We also feature in-depth interviews with company founders and some of the world's most prominent CEOs.These include Google's Sundar Pichai, Wikipedia founder Jimmy Wales, CEO of Canva Melanie Perkins, and the CEO of Starbucks, Brian Niccol.(Picture: Person standing on weighing scales. Credit: Press Association)

You can listen to the first episode of this three-part series here. GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one. Chris Hannay, The Globe's business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we'll explore access to these drugs with The Globe's health reporter Kelly Grant on who gets their GLP-1 covered by their insurance – and who doesn't. Plus, Globe audio producer Kasia Mychajlowycz leads us on a journey to understand just how the virtual pharmacies advertised all over her social media feed are vetting people who want Ozempic prescriptions. The next episode and final episode of Skinny, Inc. is next Monday, March 9. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, I'm tackling a hot topic: weight loss medication. Whether you're curious about it, considering it, or already taking it, this episode is for you.We'll chat honestly and without judgment about medications like CPI, Wegovy, and Mounjaro, which are everywhere right now. I hear from women all the time who are worried about starting, afraid of relying on medication forever, or unsure how to maintain results once they stop.I want to give you clarity on how to use these medications as a tool, not a quick fix. I share strategies that help you build sustainable habits, protect your metabolism, and set yourself up for long-term success, so you don't just lose the weight, but you keep it off.In this episode, I cover:How GLP-1 medications work and why they are not a magic pill.The most common mistakes women make while on medication that lead to regaining weight.Five essential steps for using medication responsiblyWhy focusing solely on appetite suppression won't teach consistency or create lasting habits.How to maintain your weight loss after stopping medication by working on your identity, habits, and structure.If you've been wondering, “Is this cheating?”... the answer is no. Weight loss medication can be a helpful support, but it works best when paired with the right habits and mindset.By the end of this episode, you'll understand how to use weight loss medication safely, effectively, and sustainably, so you can finally stop worrying about rebound weight gain and start feeling confident in your skin.Links & Resources:Apply for coaching: HEREFollow Angela on Instagram: HERE

Facelift da Kris Jenner, novo rosto da Anitta, pessoas magras usando Mounjaro e Ozempic para “perder alguns quilinhos”, botox preventivo, dicas de emagrecimento, chip da beleza… Se você é uma mulher e usa as redes sociais com frequência, com certeza já se deparou com esse tipo de coisa no seu feed. Às vezes parece que nós estamos ficando malucas porque toda vez que scrollamos alguma rede nos deparamos com mais famosas ou influenciadoras falando sobre os vários procedimentos estéticos que acabaram de fazer e, claro, sempre marcando o @ do médico para fazer a publi! Ao mesmo tempo, tudo isso é vendido como “saúde” e “bem-estar” e não como práticas nocivas (e, quase sempre, extremamente caras) que servem para enfraquecer e empobrecer as mulheres. No episódio #80 do Pessoal é Político, nós abordamos a popularização das cirurgias plásticas e procedimentos mostrando porque é necessário tecer críticas feministas sobre essas práticas que estão cada vez mais populares nas redes sociais.

Is what I've been doing for years helpful for achieving autophagy?When you say low carb, do you mean low complex carb or low simple and processed carb?What daily multivitamin would you recommend for a male age 50 plus?Which supplement should I take for elevated triglycerides?

Integrative Healthcare Symposium highlightsWhat supplements can help combat the side effects of cancer therapy?Will my son's use of Zepbound affect his fertility?

Éra léků na hubnutí GLP-1 (Ozempic, Wegovy, Mounjaro) přináší zásadní otázky, které přesahují hranice metabolismu a dotýkají se samotné podstaty krásy a kvality pleti. Jaký vliv má výrazný úbytek hmotnosti na elasticitu pleti a kontury obličeje? A jak na tyto změny reaguje současná estetická dermatologie?V nové epizodě série Vogue No Age se Cindy Kerberová, beauty director Vogue Czechoslovakia, setkává s MUDr. Monikou Kavkovou, vedoucí lékařkou Be Elite Clinic. Inspirací pro jejich rozhovor se stal odborný kongres IMCAS v Paříži, kde téma změn pokožky při užívání GLP-1 léků patřilo k těm nejdiskutovanějším.V této epizodě se dozvíte:Co přesně stojí za vizuální změnou tváře, pro kterou se vžil termín „Ozempic face“Jak podpořit pevnost pleti a objem obličeje v období rychlé tělesné transformaceRozdíl mezi fyziologickým stárnutím a změnami vyvolanými úbytkem podkožního tukuCestu k udržení harmonického vzhledu pomocí pokročilých metodTento díl nabízí hluboký vhled do biologie touhy po změně a přináší praktický návod i osobní zkušenost, jak skloubit moderní léčbu s No Age přístupem - tedy s úctou k sobě samým, integritě pleti a přirozenosti.

Send a textMost people think body image is about weight.It's not.Body image is about the story you learned about yourself — often long before you understood what calories or cellulite even were.In this episode, we explore:What body image actually is (and why it's not just about the mirror)How childhood experiences shape the way you see yourselfWhy we often perceive our bodies inaccuratelyThe emotional triggers that intensify body dissatisfactionWhy self-criticism doesn't create sustainable weight lossWhy even people who lose weight — including those using GLP-1 medications — can still feel deeply unhappy in their bodiesIf you've ever believed:“I'll feel better about myself when I'm thinner,” this episode gently challenges that idea.This is not about forced body positivity.It's about understanding the psychology behind body image — and learning how to stop letting it quietly run your life.Because your life is happening now.Not ten kilos from now.Thanks for listening, I hope this episode will be helpful.Philippe

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/     Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells.   After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed.  Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html   XX For years, researchers have observed that people who live at high elevations,  tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs.     In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes.     "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition.  The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

GLP-1 drugs like Ozempic, Wegovy, and Mounjaro are everywhere, there in doctors’ offices, group chats, and comment sections. For some, they’re life-changing. For others, they raise uncomfortable questions about body image, privilege, and the pressure to be thin at any cost.But what doesn’t get talked about enough is what happens when you stop.In this episode, Brianne Cail opens up about her decision to start Ozempic and Mounjaro for health reasons and followed when she had to come off them. From the financial strain to the physical and emotional impact, we unpack the realities people don’t always share out loud.Because the truth about weight, money, and medical choice? It’s more complicated than a before-and-after photo. Ozempic, Monjaro, weight loss, body image, food noise, health, personal journey, societal standards, emotional impact, medication THE KIT ARTICLE

Entering the final trading week of February, Carl Quintanilla, Jim Cramer and David Faber explored what's at stake for the markets, especially after Friday's Supreme Court ruling that struck down many of President Trump's reciprocal tariffs — and the president responding with plans to raise global tariffs by 15%. Shares of Novo Nordisk tumbled: Trial results show its next-generation obesity treatment was less effective than the Eli Lilly drug marketed as Zepbound and Mounjaro. Also in focus: The winter storm blasting the Northeast results in more than 10,000 flight cancellations, Alphabet upgraded, software stocks downgraded, AI roundup, Netflix-Warner latest from Ted Sarandos to Susan Rice and Trump. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Are you worried GLP-1 medications will make coaches obsolete? Medications like Ozempic, Wegovy, and Mounjaro are changing the weight loss conversation, but they're not replacing the work coaches do. In fact, they're making behavior change coaching more essential than ever.In this episode, Dr. Kasey Jo Orvidas breaks down what GLP-1s actually do, why 50-75% of users stop taking them within a year, and how coaches can support clients using these medications while staying ethically grounded and professionally valuable.You'll learn:What GLP-1 medications actually do (and what they don't teach clients about behavior change, mindset, or long-term habits)Why people still need coaches even when medication accelerates weight lossHow to navigate the ethical dilemma of posting client transformations when GLP-1 use is involvedSix ways coaches can support clients on GLP-1s, from muscle preservation to managing identity shifts and shameWhy the future of coaching requires more psychology, communication skills, and mindset work (not less)Watch the full episode on YouTube: https://youtu.be/gKmAYVkVbDgRegister for my FREE 3-Day Training: The Coaching CodeConnect with me on Instagram! Grab 5 Free Lessons in Mindset and Behavior Change Coaching [HMCC WAITLIST]LEAVE A REVIEW, WIN A WORKSHOP! After you leave your review, take a screenshot and upload it to this form to be entered to winWant me to answer your questions on my next Q&A episode? Drop your questions here!Related Topics: GLP-1 medications for weight loss, Ozempic and coaching, Wegovy and fitness coaches, coaching clients on weight loss medication, behavior change coaching, mindset coaching with GLP-1s, ethical coaching practices, client transformation ethics, future of health coaching, weight loss medication support, coaching industry trends, muscle preservation on GLP-1s, sustainable weight loss habits

In this episode, Gianna Beasley interviews Aja Beckett, the founder of Shotsy, a companion app for individuals on GLP-1 medications. Aja shares her personal journey with obesity and the challenges she faced before discovering GLP-1s. We dive into the struggles of weight management, the creation of the Shotsy app, its features, and the importance of community support. Shotsy is a mobile health tracking app specifically designed for people using GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Semaglutide, and Tirzepatide. It helps users monitor their injection schedule, side effects, and progress toward goals like weight loss or health improvements. Aja discusses the app's freemium model, ensuring accessibility for all users, and discusses the significance of building trust within the GLP-1 community.Download Shotsy in the App Store on Apple or Android!

Medsafe has quietly approved another weight loss drug, Mounjaro, which is now available by prescription in some New Zealand pharmacies. Obesity doctor, Dr Chaey Leem spoke to Ingrid Hipkiss.

Será que o uso de Mounjaro é o que irá resolver seu caso e te fazer finalmente ser magra? Vamos descobrir hoje se ele é para seu metabolismo ou não.

Queda de cabelo, fraqueza e intestino parado. Vamos falar do preço metabólico da falta de nutrientes e como reverter isso.Bônus: Suplementos que podem ajudar para quem estiver usando GLP-1Se você está usando análogos de GLP-1 (como Ozempic, Mounjaro, Wegovy) para emagrecer, é provável que esteja feliz com os números caindo na balança, mas... exausta na vida real.Sabe aquela sensação de corpo pesado? De fraqueza para subir um lance de escada? Aquele cabelo caindo mais que o normal e uma “névoa” mental que não passa?Não, não é “coisa da sua cabeça”. E não vale colocar na conta da menopausa também não. E não, não é o preço que você precisa necessariamente pagar para ser magra — se souber fazer direito.Compreenda por que emagrecer sem suporte metabólico leva à magreza frágil, ao efeito rebote e ao colapso da vitalidade. E, principalmente, como usar essas medicações do jeito certo, com estratégia, nutrição e proteção muscular.Neste episódio, você vai aprender:Por que estar magra não significa estar saudávelComo a perda de apetite leva ao modo racionamento metabólicoO risco real da perda muscular silenciosa com GLP-1Por que perder músculo acelera o envelhecimento e o efeito reboteO impacto das “canetinhas” no intestino, digestão e SIBOComo fazer o uso correto dos GLP-1 com suporte metabólicoEstratégias de proteína, treino e suplementação para preservar energiaComo reverter cansaço, fraqueza, queda de cabelo e intestino paradoMeu livro Perimeno Quê? O manual que eu queria ter tido quando eu passei pela perimenopausa já está disponível para vendas.

In den USA nehmen inzwischen rund 12 % der Erwachsenen GLP-1-Medikamente wie Wegovy, Ozempic oder Mounjaro – ursprünglich zur Behandlung von Diabetes entwickelt. Und der Trend beschränkt sich längst nicht mehr nur auf die USA: Weltweit greifen Millionen Menschen zu den Abnehmspritzen. Das Prinzip ist simpel: weniger Appetit. So sollen Gewichtsverluste von 14 bis 22 % möglich sein. Unser Dauerpraktikant hat es ausprobiert…

I've been sick all week, and it completely disrupted my plans, my workouts, and the momentum I thought I was building.In this episode, I'm talking about what it feels like when your body forces you to rest — and why we often only “allow” ourselves to slow down when we're physically unwell. If you're feeling behind, off track, or like you have to start over, this is your reminder: you're not starting over. You're continuing.Show Notes!

We start off talking about a man in Louisiana who has been arrested for the 3rd time for deceiving people into changing his diaper, an Army colonel who traded secrets for attention, the weird side effects of GLP-1s and Mounjaro Penis! LINKS:Man poses as disabled so nanny will change his diapers, police sayEx-Army colonel at MacDill shared classified battle plans to woo womanWeight-loss drugs could increase risk of malnutrition-related disease | Fox NewsMan shares experience with ‘Mounjaro penis' that added ‘3 inches' to manhoodThe Treehouse Show is a Dallas based comedy podcast. Leave your worries outside and join Dan O'Malley, Trey Trenholm, Raj Sharma, and their guests for laughs about funny news, viral stories, and hilarious commentary.The Treehouse WebsiteGet MORE from the Treehouse Show on PatreonTreehouse YouTube ChannelGet a FREE roof inspection from the best company in DFW:Cook DFW Roofing & Restoration CLICK HERE TO DONATE:The RMS Treehouse Listeners Foundation

In today's episode, I'm sharing Week 3 of this very personal series where I'm documenting grief alongside my health and weight loss journey. Normally, we talk about fitness, mindset, and taking practical steps forward—but this series is about what happens when life hits hard and everything feels shaken. I lost my dad recently after years of dementia, and this episode is recorded just after laying him to rest. I talk openly about the funeral, the emotions that surprised me, the moments of laughter mixed with sadness, and the experience of saying goodbye in a way that felt deeply human, imperfect, and real. Dementia is cruel. It doesn't just affect one person—it changes families, routines, plans, and futures. For years, it quietly controlled our lives, and now there's space where that constant pressure once lived. In this episode, I reflect on what that space feels like, and how I'm beginning to steady myself again. Because even in grief, I know one thing to be true: change doesn't happen without action. With Lent beginning, I share what I'm choosing to stop doing—not coffee, not chocolate—but the habit of finding reasons not to move my body. I'm committing to moving three times a week for at least 30 minutes and writing it down, without worrying about perfection. Walking, classes, fresh air, even walking up to the cemetery to say hello to my dad—all of it counts. This episode is messy, emotional, and unfinished—and that's exactly the point. I invite you to reflect on your own journey and ask yourself: What could you do for your health that doesn't need to look perfect? What small action could you take, even if life feels chaotic? Where might you be waiting for the “right time” instead of taking a step now? Grief doesn't come with rules, timelines, or neat edges. Neither does progress. If you're navigating loss, feeling stuck, or struggling to find your footing again, I hope this episode reminds you that it's okay to move forward while still hurting—and that doing something imperfectly is still doing something. I'll be back for Week 4 to share how things are settling and how this commitment to movement is going. Thank you for listening. Thank you for holding space for my dad's memory. And thank you for being here with me.  

Recent Cochrane reviews commissioned by the World Health Organization show that blockbuster weight loss drugs like Ozempic deliver substantial results. According to ScienceDaily reporting on February 11, these GLP-1 drugs, including semaglutide in Ozempic and tirzepatide in Mounjaro, lead to average weight losses of 11 to 16 percent over one to two years in people with obesity, far outperforming placebos in trials with thousands of participants. Tirzepatide achieved about 16 percent reduction after 12 to 18 months, while semaglutide hit roughly 11 percent after 24 to 68 weeks, with benefits lasting as long as treatment continues. However, most studies were funded by drugmakers, long-term safety data remain limited, and common side effects like nausea affect many users.A Rutgers Health study published this week in the Journal of Medical Internet Research, as reported by Healthline on February 16, reveals that Ozempic users often prioritize weight loss over these side effects. Researchers analyzed online reviews and found that 67 percent reported reduced appetite and cravings alongside weight loss, making them satisfied enough to continue despite gastrointestinal issues in 62 percent of cases. Lead author Abanoub Armanious noted that everyday users value efficacy highly, even tolerating discomfort that prompts some to stop other treatments. Bariatric surgeon Mir Ali added that patients paying out of pocket show strong motivation, often seeking remedies for nausea rather than quitting.Novo Nordisk announced on February 17 that a new clinical study demonstrated people lost about 21 percent of their body weight on average with their obesity treatment, highlighting ongoing advancements in GLP-1 therapies. No fresh comments from Oprah Winfrey on Ozempic emerged this week, though her past support underscores the cultural buzz around these medications.Experts like Juan Franco from Heinrich Heine University emphasize the excitement after decades without effective options, but call for independent long-term studies on heart health, quality of life, and weight regain after stopping. Access issues persist due to high costs, though semaglutide patents expire this year, potentially lowering prices.Thanks for tuning in, listeners, please subscribe, come back next week for more, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Send a textWegovy's new 7.2 mg dose—three times higher than the current max—has just been approved in the EU, with U.S. approval expected soon. But now that Wegovy matches Zepbound on weight loss, the real question isn't which drug helps you lose more weight—it's which one treats your underlying metabolic disease more effectively.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Part 2 picks up right where Part 1 ends—and goes deeper into what people are really wondering: What's safe? What's real? And who can I trust? Jamie and Jaclyn  talk about how misinformation spreads, why some people experience negative outcomes (often by skipping proper dosing, labs, and provider follow-ups), and why these wellness tools are most powerful when used with structure and medical guidance. You'll also hear a transformation story that's bigger than weight—one that changed energy, marriage, medications, and an entire family's trajectory. This episode is a reminder that the first step isn't dramatic… it's brave. www.YourHealth.Org

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic from medical breakthroughs to real-life health impacts.Recent Cochrane reviews commissioned by the World Health Organization show that Ozempic, or semaglutide, leads to about eleven percent average weight loss after six to eighteen months in people with obesity, outperforming placebo in eighteen trials with nearly twenty-eight thousand participants. Tirzepatide, like Mounjaro, achieves even more at sixteen percent, while liraglutide offers four to five percent. These glucagon-like peptide-one drugs mimic a hormone that slows digestion and boosts fullness, originally for type two diabetes but now key for weight management with diet and exercise.Cochrane researchers note benefits persist during treatment but highlight gaps: most trials were industry-funded, long-term safety data is limited, and side effects like nausea affect many, with some dropping out. No clear edge on heart events or death versus placebo yet.A Rutgers Health study in the Journal of Medical Internet Research analyzed sixty online reviews and found sixty-seven percent of users report weight loss, less appetite, or fewer cravings, making them stick with it despite nausea or vomiting in sixty-two percent. Lead author Abanoub Armanious says everyday experiences show benefits often outweigh gut issues for motivated users. Bariatric expert Mir Ali adds diarrhea or pain prompts more quits than nausea.Newer buzz includes Ozempic face: rapid fat loss causes gaunt cheeks, per a Gujranwala Medical College analysis and American Academy of Facial Plastic and Reconstructive Surgery survey, boosting filler demand by fifty percent. Weight regain post-treatment is common, stressing lifestyle pairing.Wegovy now offers semaglutide pills like Rybelsus, matching injections for seventeen percent loss with changes, per Prisma Health's Eva Wolf.Listeners, blend these tools with habits for lasting wins. Thanks for tuning in—subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome to this weeks episode, I'm actually recovering from knee surgery that took a bit longer to recover from than anticipated.This episode was one of the first episodes I ever recorded in 2023 and I wanted to share it again since many of us will never scroll that far back- so we're gonna throw it back with some real life vulnerability! In this episode I delve deeper into my own experience with body image and self-esteem, and how I overcame my own insecurities. In this episode we cover:Connecting to the people I work withSizing, self-esteem and being in photos Learning to be proud of myselfA turning point in my body imageThe mental side of physical health Being comfortable in the uncomfortable Rewiring the way you think about your body 

במאה ה-20 תעשיית המזון וההסעדה נבנתה על ארכיטקטורה של דחפים, על היכולת של המלח, הסוכר והשומן לעקוף את מנגנוני השובע שלנו ולייצר מעגל אינסופי של "עוד". אבל בשנים האחרונות מתפשטת בעולם טכנולוגיה חדשה שמציעה למשתמשים חומת מגן כימית שמשתקת את הרעש, את התשוקה. הטכנולוגיה הזו מכניסה תוכן חדש לשיחה שמתנהלת בין הלבלב לבין אזור במוח שנקרא היפותלמוס, והתוכן הזה גורם לאלו שמשתמשים בתרופות שמבוססות עליה, Ozempic, Wegovy, Mounjaro ותרופות אחרות, להרגיש שהם... שבעים.סקרים שנערכו בסוף 2025 הראו שכ-1 מכל 8 מבוגרים בארה"ב התנסה בתרופות האלו ויש וההערכות לפיהן עד לשנת 2030 הן יהפכו לקטגוריית התרופות הנמכרת בהיסטוריה של עולם הרפואה.כולנו עסוקים בבינה מלאכותית אבל המהפכה השקטה ביותר של המאה ה-21 לא מתרחשת במשרדי חברות הטכנולוגיה שעמק הסיליקון ובתוך המחשבים שלנו - היא מתרחשת בתוך הגוף שלנו והיא נשענת על טכנולוגיה רפואית. אבל בדומה למהפכה הרועשת, ההשפעות של המהפכה השקטה הן נרחבות, עמוקות ומפתיעות.קישורים:מחקר: ירידה של 8% בהוצאות בסופרמרקט בקרב נוטלי תכשירי GLP-1https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buyהפרסומת ל-Wegovyhttps://www.youtube.com/watch?v=7Y6zH5bm2eYספר: על הקשר שבין מזון מהיר והמכונית הפרטיתhttps://www.amazon.com/Fast-Food-Roadside-Restaurants-Automobile/dp/0801861098

Today I'm joined by Dr Courtney Raspin, a Chartered Counselling Psychologist and Clinical Director of Altum Health, a specialist eating disorders and mental health clinic in London. Courtney has over 25 years of clinical experience, including a decade in one of the NHS's largest eating disorder services.She's just co-authored a book called The Weight Loss Prescription with psychiatrist Dr Max Pemberton (available 26th Feb!) - a book about the psychology of GLP-1 weight loss medications like Wegovy and Mounjaro. Given her background in eating disorders, Courtney has a nuanced perspective on weight loss medications, which I think is really important to hear.If you're in eating disorder recovery and feeling unsettled by the rise of GLP-1 medications… if you've noticed feelings of jealousy, confusion or fear around them… or if you're trying to understand where health support ends and diet culture begins, this conversation is for you.Key Takeaways:How Courtney's work in eating disorders shaped her approach to weight managementThe warning signs of high drive for thinnessWhy weight loss doesn't automatically improve body imageThe difference between body neutrality and body positivityWhy GLP-1 medications aren't inherently harmfulThe risks of unregulated access, online prescribing, and counterfeit medicationThe various causes of “food noise” and why GLP-1 medications may helpWhat psychological support in weight management actually involvesCourtney's guidance on GLP-1s and eating disorder recoveryTimestamps:00:00 Courtney's journey into weight management05:00 Body neutrality and realistic body image work08:30 Understanding GLP-1s: benefits, risks and misconceptions12:00 Food noise and why context matters16:00 The psychological work behind lasting change21:00 Health vs the thin ideal27:00 Tensions within the ED field and professional responses31:30 What to consider before starting GLP-1s34:30 Courtney's book and final adviceResources & LinksFollow @drcourtneyraspin on InstagramConnect with Us:Subscribe to the Full of Beans PodcastFollow Full of Beans on InstagramCheck out our websiteListen on YouTube⚠️ Trigger Warning: Mentions of eating disorders (anorexia, bulimia, binge eating), restriction, weight loss, GLP-1 medications, and body image. Please take care when listening.If you enjoyed this episode, don't forget to subscribe, rate, and share the podcast to help us spread awareness.Sending positive beans your way, Han

במאה ה-20 תעשיית המזון וההסעדה נבנתה על ארכיטקטורה של דחפים, על היכולת של המלח, הסוכר והשומן לעקוף את מנגנוני השובע שלנו ולייצר מעגל אינסופי של "עוד". אבל בשנים האחרונות מתפשטת בעולם טכנולוגיה חדשה שמציעה למשתמשים חומת מגן כימית שמשתקת את הרעש, את התשוקה. הטכנולוגיה הזו מכניסה תוכן חדש לשיחה שמתנהלת בין הלבלב לבין אזור במוח שנקרא היפותלמוס, והתוכן הזה גורם לאלו שמשתמשים בתרופות שמבוססות עליה, Ozempic, Wegovy, Mounjaro ותרופות אחרות, להרגיש שהם... שבעים.סקרים שנערכו בסוף 2025 הראו שכ-1 מכל 8 מבוגרים בארה"ב התנסה בתרופות האלו ויש וההערכות לפיהן עד לשנת 2030 הן יהפכו לקטגוריית התרופות הנמכרת בהיסטוריה של עולם הרפואה.כולנו עסוקים בבינה מלאכותית אבל המהפכה השקטה ביותר של המאה ה-21 לא מתרחשת במשרדי חברות הטכנולוגיה שעמק הסיליקון ובתוך המחשבים שלנו - היא מתרחשת בתוך הגוף שלנו והיא נשענת על טכנולוגיה רפואית. אבל בדומה למהפכה הרועשת, ההשפעות של המהפכה השקטה הן נרחבות, עמוקות ומפתיעות.קישורים:מחקר: ירידה של 8% בהוצאות בסופרמרקט בקרב נוטלי תכשירי GLP-1https://news.cornell.edu/stories/2025/12/ozempic-changing-foods-americans-buyהפרסומת ל-Wegovyhttps://www.youtube.com/watch?v=7Y6zH5bm2eYספר: על הקשר שבין מזון מהיר והמכונית הפרטיתhttps://www.amazon.com/Fast-Food-Roadside-Restaurants-Automobile/dp/0801861098מקווים שנהנתם ואם כן אל תשכחו לדרג ולעקוב אחרי הפודקאסט.אל תשכחו להצטרף לניוזלטר השווה שלנו בלחיצה כאן. 

Send a textWhat happens when weight loss becomes… easy?In this candid conversation, I sit down with a fellow therapist and friend Lucy Cavendish who has been taking Mounjaro (a GLP-1 medication) and has experienced significant weight loss. We explore the undeniable benefits of these injections — reduced appetite, quieter food noise, and the relief of finally seeing the scale move.But we don't stop there, we ask the deeper questions:What role did emotional triggers play in the weight gain to begin with?What happens when the injections stop?Can changing your body change how you feel about yourself?And how do we prevent old coping mechanisms from creeping back in?This episode isn't anti-medication. It's about integration.GLP-1s like Mounjaro can be powerful tools. But sustainable change often requires understanding the story behind the weight — the stress, grief, trauma, burnout, habits, identity shifts — and making sure those triggers aren't waiting quietly in the background.If you're considering these injections, currently taking them, or navigating weight loss while working on your relationship with food and your body, this episode will help you think beyond the scale.Because sometimes losing weight is the easy part.Understanding it is the real work.Thanks for listening, I hope this episode will be helpful.Philippe

Confira os destaques do Jornal da Manhã desta sexta-feira (13): O ministro Dias Toffoli deixou oficialmente a relatoria do inquérito que investiga as fraudes bilionárias no Banco Master nesta quinta-feira (12). A decisão foi anunciada após uma reunião administrativa de emergência convocada pelo presidente da Corte, Edson Fachin, que contou com a participação de todos os dez ministros. Em nota conjunta, os magistrados negaram a existência de suspeição ou impedimento legal de Toffoli, reafirmando o apoio institucional ao colega, mas informaram que o próprio ministro solicitou a redistribuição dos processos para preservar os “altos interesses institucionais” do tribunal diante do desgaste causado pelas recentes revelações. Para falar sobre o assunto, a Jovem Pan entrevista Gustavo Sampaio, professor de direito constitucional. Nesta quinta-feira (12), o presidente dos Estados Unidos, Donald Trump, afirmou em um post na rede social Truth Social que as relações entre Washington e a Venezuela têm sido “extraordinárias”, elogiando o secretário de Estado Marco Rubio e outros representantes do governo pela condução da política externa naquele país. Trump destacou que o petróleo venezuelano está “começando a fluir” e que grandes quantias de recursos, que não eram vistas há muitos anos, devem ajudar o povo venezuelano em breve. O vice-presidente e ministro da Indústria, Geraldo Alckmin, afirmou nesta quinta-feira (12) que é contra o projeto de lei que prevê a quebra de patentes do Mounjaro e do Zepbound, duas marcas de canetas emagrecedoras. A renúncia de Chris Wormald, secretário de gabinete e um dos principais nomes do governo britânico, aprofundou a crise enfrentada pelo primeiro-ministro Keir Starmer após novas revelações ligadas ao caso Jeffrey Epstein. Wormald se tornou o terceiro integrante da equipe a deixar o cargo em poucos dias. A situação ganhou ainda mais pressão após o nome de Peter Mandelson aparecer em fotos e extratos bancários associados ao escândalo. A Justiça suspendeu liminarmente regras das escolas cívico-militares do estado de São Paulo, sob argumento de que há evidência de violação ao princípio da legalidade, ofensa ao princípio da gestão democrática do ensino e potencial discriminatório. A deputada federal Adriana Ventura (Novo-SP) iniciou a coleta de assinaturas na Câmara dos Deputados para viabilizar a tramitação de uma Proposta de Emenda à Constituição que prevê a obrigatoriedade de códigos formais de conduta e integridade no Judiciário brasileiro. A proposta pretende estabelecer diretrizes éticas para ministros do STF e de outros tribunais superiores, ampliando mecanismos de controle e transparência institucional. O Governo de São Paulo lançou um alerta à população sobre os riscos do consumo de bebidas alcoólicas adulteradas durante o Carnaval. A campanha reforça a importância de comprar apenas em estabelecimentos regularizados, verificar a procedência dos produtos e evitar itens de origem desconhecida. Segundo o Centro de Vigilância Sanitária de São Paulo, ações de fiscalização serão intensificadas em parceria com vigilâncias municipais, responsáveis pela inspeção de comércios e vendedores ambulantes. Nesta sexta-feira (13), primeira noite do Carnaval em São Paulo, a Mocidade Unida da Mooca, estreante no grupo especial, abre os desfiles a partir das 23h, enquanto a Barroca Zona Sul será a última a entrar no sambódromo, com início previsto para as 5h30 de sábado (14). Ao todo, serão sete escolas na sexta e mais sete no sábado; das 14 agremiações que participam neste fim de semana, duas serão rebaixadas após a apuração das notas marcada para as 16h de terça-feira (17). Essas e outras notícias você acompanha no Jornal da Manhã. Learn more about your ad choices. Visit megaphone.fm/adchoices

Kathleen discusses her 24-year journey using Type 1 tools for Type 2 management. She covers Mounjaro success, evolving tech, and why CGMs now beat alert dogs. Free Juicebox Community (non Facebook) Type 1 Diabetes Pro Tips - THE PODCAST Eversense CGM Medtronic Diabetes Tandem Mobi ** Use code JUICEBOX to save 40% at Cozy Earth  CONTOUR NextGen smart meter and CONTOUR DIABETES app Dexcom G7 Go tubeless with Omnipod 5 or Omnipod DASH * Get your supplies from US MED  or call 888-721-1514 Touched By Type 1 Take the T1DExchange survey Apple Podcasts> Subscribe to the podcast today! The podcast is available on Spotify, Google Play, iHeartRadio, Radio Public, Amazon Music and all Android devices The Juicebox Podcast is a free show, but if you'd like to support the podcast directly, you can make a gift here or buy me a coffee. Thank you! *The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.  ** t:slim X2 or Tandem Mobi w/ Control-IQ+ technology (7.9 or newer). RX ONLY. Indicated for patients with type 1 diabetes, 2 years and older. BOXED WARNING:Control-IQ+ technology should not be used by people under age 2, or who use less than 5 units of insulin/day, or who weigh less than 20 lbs. Safety info: tandemdiabetes.com/safetyinfo Disclaimer - Nothing you hear on the Juicebox Podcast or read on Arden's Day is intended as medical advice. You should always consult a physician before making changes to your health plan.  If the podcast has helped you to live better with type 1 please tell someone else how to find it!  

Silver, Gold and Crypto (oh my) Hang on – Wild ride here Superbowl, Olympics- Wait until you hear about the CAPex spending! Shakeup in Dietville PLUS we are now on Spotify and Amazon Music/Podcasts! Click HERE for Show Notes and Links DHUnplugged is now streaming live - with listener chat. Click on link on the right sidebar. Love the Show? Then how about a Donation? Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter Interactive Brokers  Warm-Up - Silver, Gold and Crypto (oh my) - Need a stock for CTP - Hang on - Wild ride here - Superbowl, Olympics- Wait until you hear about the CAPex spending! - Shakeup in Dietville Markets - Massive moved during the week - - Bitcoin clipped $60k before rebounding - DJIA tops 50,000 for the first time - Wait until you hear about the CAPex spending! - CAT == 1,100 points on the DJIA in 2026 Superbowl and Superbowl ads - Game review - Any ad stick out? - $10M per ad this year - Half Time with Bad Bunny? - Anthropic busting on OpenAi Last Week! - Massive moved - quick calc showed that about $1T was wiped from market caps in the sell-off, particularly in tech names. - HOWEVER - Friday alone is estimated to have added $1.5T to market cap AI Ripping Through - Plenty of names getting cooked over AI announcements - First it was the software companies - Now there are names in legal and finance that got clocked - Today - Altruist.ai can do tax planning and that hurt companies in financial space Earnings Season Update - Reporting so far: 59% of S&P 500 companies have reported Q4 2025 results. - Beat rate: 76% have topped EPS estimates (vs. 5-yr average: 78% (slightly lower) vs. 10-yr average: 76% (in line) - Magnitude of beats (aggregate): earnings are 7.6% above estimates vs. 5-yr average: 7.7% (about the same) vs. 10-yr average: 7.0% (a bit better) - Nothing great,  like Goldilocks Earnings Highlights - Palantir (PLTR): Reported strong Q4 results early in the week , beating estimates with revenue ~$1.41B (vs. ~$1.33B expected) and EPS $0.25 (vs. $0.23). Guidance for 2026 was upbeat (~61% revenue growth). Shares rallied sharply initially (~7–11% post-earnings), but gave back some gains amid broader tech volatility (e.g., down ~11–22% in parts of the week from peaks). - AMD: Reported mid-week, beating EPS (~$1.53 vs. lower expectations) with solid data center growth (~39%). However, Q1 guidance disappointed relative to high expectations in the AI chip space. Shares sank dramatically — down ~15–17% the next day, with some reports noting up to 20%+ drops at points, contributing to broader chip sector pressure. - Alphabet (GOOGL/GOOG): Reported beating on revenue (~$113.8B) and EPS (~$2.82), with strong core performance. But capex guidance for 2026 ($175–$185B, roughly double prior levels) sparked AI spending worries. Shares dipped post-earnings (down ~0.5–5% initially, flat to lower the next day, with some volatility pulling it below key moving averages). - Amazon (AMZN): Reported after hours on February 5, with mixed results — EPS ~$1.95 (narrow miss vs. ~$1.97 expected), but solid overall. The big negative was a surprise $200B capex forecast for 2026 (well above expectations), tied to AI/cloud buildout. Shares plunged sharply — down ~7–10% in after-hours/extended trading, with Friday moves around -5–8% in some sessions. Recent Tech CAPEX announcements - Amazon (AMZN) — Guided to approximately $200 billion in capex for 2026 (a massive jump from ~$125–131 billion in 2025, with ~80% likely AI-related per analyst commentary). This was the largest single-company figure and a major surprise, contributing heavily to the week's "wild" reactions. - Alphabet (GOOGL/GOOG) — Guided to $175–185 billion in capex for 2026 (roughly double the $91 billion spent in 2025, far above analyst expectations of ~$115–119 billion). Emphasis was on AI compute capacity, servers, data centers, and networking to meet demand for Gemini and cloud services. - Meta Platforms (META) — Guidance from late January (but heavily discussed last week): $115–135 billion for 2026 (up significantly from ~$70–72 billion in 2025, potentially an ~87% increase). - Microsoft (MSFT) — No new full explicit 2026 guidance in early February (fiscal year runs July–June), but recent quarterly run-rate and analyst projections put it around $97–145 billion (with some sources citing ~$105 billion or higher based on Q2 spending trends and signals of continued growth from prior levels of ~$88 billion in FY2025). ------!!!!Combined 2026 capex projected at $635–665 billion (low/high ends) or up to $650–700 billion in some reports — a ~60–74% increase from their collective ~$381 billion in 2025. Market Reaction from all of this.... - Markets were a bit spooked on the Anthropic announcement earlier in the week - software sold off and set a sour mood - Microsoft dumped pretty hard as the amount of spend was higher than anticipated, especially with some slower growth in Azure. - Amazon took a beating on the increased spend they anticipate *(extra by $50B) - BUT: Friday markets rallied as there was realization that the $200B spend by Amazon would seep into the economy and fuel infrastructure spending along with chips, tech etc. Other Earnings of Interest -  Reddit reported fourth-quarter earnings on Thursday in which the social media company beat on the top and bottom lines. - The company said it expects first-quarter sales to come in the range of $595 million to $605 million, which is higher than Wall Street expectations of $577 million. - Reddit also announced a $1 billion share repurchase program. - Reddit gets about $250 million a year from OpenAi and Google to have your data for training their LLMs While we are on the subject - Friday, DJIA hit 50,000 - first time ever! - Up 1,200 point of which approx 350 was from caterpillar and 280 was from Goldman Sachs Hats off to WalMart - Walmart Inc. shares pushed its market capitalization past $1 trillion on Tuesday for the first time ever| - Big transformation over the pst year - Walmart has maintained its appeal to households looking for value, its online offerings are drawing new, wealthier shoppers seeking convenience. Google Bond Offering - Issuing several tranches of bonds, denominated in Stirling - one as long as 100 years - Would you buy that? - The Google parent is set to raise $20 billion from a US dollar bond offering on Monday — more than the $15 billion initially expected — and is also pitching investors on what would be its first ever offerings in Switzerland and the UK. - The latter would include a rare sale of 100-year bonds, the first time a tech company has tried such an offering since the dotcom frenzy of the late 1990s Fat Profits in Dietville - Really interesting sequence of events happening... - Hims launches compounded pill at prices as low as $49 per month - Analysts cite questions on efficacy, legality of pill - Hims' move shifts focus from Novo's strong Wegovy pill launch - Broader obesity market whipsawed as pricing pressure rises THEN.. - Hims and Hers Health shares dive 14% after hours on Friday (Down 25% on Monday) - FDA cites concerns over quality, safety, federal law - The U.S. Food and Drug Administration said on Friday it would take action against telehealth provider Hims & Hers, for its $49 weight-loss pill, including restricting access to the drug's ingredients and referring the company to the Department of Justice for potential violations of federal law. AND.... - Eli Lilly last Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. - The pharmaceutical giant anticipates its 2026 revenue will come in between $80 billion and $83 billion. Analysts expected revenue of $77.62 billion, according to LSEG. - Meanwhile, NOVO had a really bad outlook that took the shares down 13% after the report. Japan Markets Soar - Japanese stocks jumped to a record high Monday, leading gains in the region after Prime Minister Sanae Takaichi won a landmark election victory. - The ruling Liberal Democratic Party captured a two-thirds supermajority in the 465-seat lower house, public broadcaster NHK reported. - Japan's Nikkei 225 jumped past 57,000 for the first time before paring gains to close 3.9% higher at 56,363.94, while the Topix also notched a record high, closing at 3,783.94, up 2.3%. Employment Report? - Government shutdown is forcing them to postpone again (Which is dumb) - Number due this Wednesday - Maybe because of this:U.S. employers announced 108,435 layoffs for the month, up 118% from the same period a year ago and 205% from December 2025. The total marked the highest for any January since 2009. - At the same time, companies announced just 5,306 new hires, also the lowest January since 2009, which is when Challenger, Gray & Christmas began tracking such data. - Also, job openings fell sharply in December to 6.54 million, to their lowest since September 2020. - Available jobs are down by more than 900,000 just since October. - NO! Ai and advancements in tech have noting to do with this! NO NO NO M&A - Texas Instruments Inc. has reached an agreement to buy Silicon Laboratories Inc. for about $7.5 billion, deepening its exposure to several markets for chips. - Silicon Labs investors will receive $231 in cash for each share of the company's common stock and the transaction is expected to close in the first half of 2027. - The transaction still needs to win approval by investors in Silicon Labs and shares of Silicon Labs surged by 51% to $206.48 after the announcement. Inflation - This helps - PepsiCo (PEP.O), opens new tab will cut prices on core brands such as Lay's and Doritos by up to 15% following a consumer backlash against several previous price hikes, the snacks and beverage maker said on Tuesday after it topped fourth-quarter results. Miran - Moving - Federal Reserve Governor Stephen Miran is leaving his post as chair of the Council of Economic Advisers, CNBC has confirmed. - He joined the CEA in January 2025, but had been on leave from that post since last September when he filled the unexpired term of former Fed Governor Adriana Kugler.- He reamins on Fed board No Biggie???? - There are some astonishing cased being reported of Bad AI in the operating room - JNJ's TruDi Navigation System - Since AI was added to the device, the FDA has received unconfirmed reports of at least 100 malfunctions and adverse events. - At least 10 people were injured between late 2021 and November 2025, according to the reports. Most allegedly involved errors in which the TruDi Navigation System misinformed surgeons about the location of their instruments while they were using them inside patients' heads during operations. - Cerebrospinal fluid reportedly leaked from one patient's nose. In another reported case, a surgeon mistakenly punctured the base of a patient's skull. In two other cases, patients each allegedly suffered strokes after a major artery was accidentally injured. Cuba - The main airport has putt out a bulletin that they are out of Jet Fuel - Blackouts and lack of other fuels are creating big problems - No airlines have stopped running at this point, but many will as they cannot refuel - This is a bigger problem for cargo planes (supplies) that may not be able to risk flying to Cuba as they will not be able to get out. Love the Show? Then how about a Donation? ANNOUNCING THE WINNER OF THE THE CLOSEST TO THE PIN CUP 2025 Winners will be getting great stuff like the new "OFFICIAL" DHUnplugged Shirt!     FED AND CRYPTO LIMERICKS   See this week's stock picks HERE Follow John C. Dvorak on Twitter Follow Andrew Horowitz on Twitter

Would you believe that there's a medication that can quiet the constant mental chatter around food for the first time in your adult life, but it could also cause you to lose muscle, age your face, and trap you in a cycle that's hard to escape? Both of those are true. When a drug can help someone lose 50 pounds and get off diabetes medication, that's a miracle. But when that same drug leaves someone unable to eat, losing muscle, and facing a lifetime of injections just to maintain their weight—that's a conversation we truly need to have. So, today we're taking a deep dive into GLP-1s—Ozempic, Wegovy, Mounjaro, and what's coming next. How to preserve muscle when taking GLP-1 medications Consume 1.2–1.6 g of protein per kilogram of body weight daily, spread across meals  Try to eat something containing 25–30 grams of protein within about two hours after doing a strength workout Consume easily digestible protein sources when your appetite is low (shakes, yogurt, collagen, or bone broth) Commit to doing resistance training at least two to three times a week Monitor your body composition for any early signs of muscle loss  Bio: Stephanie Gray Stephanie Gray, DNP, MS, ARNP, AGNP-C, ABAAHP, FAARFM, is a functional medicine provider helping men and women build sustainable, optimal health and longevity. A nurse practitioner since 2009, Dr. Gray completed her doctorate focusing on estrogen metabolism from the University of Iowa in 2011 and holds a Master's in Metabolic Nutritional Medicine from the University of South Florida's Medical School. Dr. Gray is one of the Midwest's most credentialed female healthcare providers. She completed an Advanced Fellowship in Anti-Aging, Regenerative, and Functional Medicine in 2013 and became Iowa's first BioTe certified provider—now the state's only platinum provider with over 10,000 pellet placements. She is also certified as a SIBO doctor-approved practitioner, mold-literate provider, and ReCODE 2.0 practitioner for cognitive decline prevention. An Amazon best-selling author, Dr. Gray wrote Your Longevity Blueprint and Your Fertility Blueprint, and hosts the Your Longevity Blueprint podcast. She co-founded Your Longevity Blueprint Nutraceuticals with her husband, Eric. After her own ten-year fertility journey, she now specializes in helping couples optimize reproductive health through functional medicine. Having lost her grandmother to vascular dementia, she is personally committed to helping families avoid cognitive decline. Dr. Gray founded the Integrative Health and Hormone Clinic in Hiawatha, Iowa. In this episode: How muscle preservation becomes non-negotiable when your appetite is suppressed Why protein timing matters more than total calories when on GLP-1 medications The importance of resistance training when taking GLP-1s The value of in-body scans for catching any muscle loss that may be occurring early on Why tapering off GLP-1 medications starts on day one, not at the finish line How natural GLP-1 stimulation can support or extend the effects of GLP-1 medications Why body composition, not weight loss, determines long-term outcomes when taking GLP-1s How the next generation of GLP-1 agonist drugs could improve our longevity Links and Resources: Relative Links for This Show: Use CODE BERBERINE to get 10% off ⁠⁠⁠Berberine  ⁠⁠⁠⁠⁠⁠Use Code FIBER to get 10% off GLP-1 Fiber Follow Your Longevity Blueprint  On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online   Follow Dr. Stephanie Gray  On Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast

Have you ever quietly wondered if Ozempic or Mounjaro would just make this whole weight thing easier? In this short episode, I explore why weight feels especially hard for women in midlife and what these medications are actually doing beneath the surface. We talk hormones, stress, insulin, and why willpower is rarely the real issue. If you feel stuck despite doing “all the right things,” there is a reason. Want to understand what is really driving your weight? Join my live masterclass, Why Does Weight Feel So Hard for Women? where I break down the root causes and what actually works for sustainable, hormone supportive fat loss. Register here.

During Sunday's Super Bowl in California, a flurry of ads from drug manufacturers and telehealth companies implored viewers at home to "ask their doctor” about a class of weight loss drugs, known as GLP-1s. These medications — like Mounjaro and Wegovy — have become ubiquitous. In just a few short years, they've transformed the way we live, move, and eat, whether we take them or not. And access and demand are only increasing, as pill forms of the drugs come onto the market. But where did they come from? And how are they reshaping our world? Today, we speak to Giles Yeo, a professor of molecular neuroendocrinology at the University of Cambridge, about the so-called weight loss revolution.Producer: Xandra EllinExecutive producer: Bridget HarneySound engineer: Travis EvansSenior news editor: China Collins(Photo: Someone using a set of weighing scales. Chris Radburn/PA)

Lately, the world is heavy. Overwhelming. At times, even unsafe. And I'll be honest, it's been hard to show up and talk about things like body image, weight, or self-care when everything around us feels so serious.But then I watched the Super Bowl halftime show and Bad Bunny showing up boldly, joyfully, unapologetically, and it brought me back to a quote that stopped me in my tracks: joy is part of the resistance.In this episode, I'm sharing a very real moment of burnout. One where I was so overwhelmed I would've rather gone to the emergency room than keep dealing with life, even though nothing was physically wrong. We talk about the kind of society we're living in, where people secretly wish for a stomach virus just to get a break, and what it means when rest only feels allowed through sickness.I share why a glow up has shifted from nice-to-have to need-to-have — focusing first on the inside, not the outside — and how choosing movement, care, joy, and self-respect isn't avoidance, it's survival.If you feel exhausted, overwhelmed, and weighed down by the world around you, this episode is for you.

Send a textThis week on The Weekly Dose, Dave Knapp breaks down the biggest questions shaking up the GLP-1 world. From whether patients should be stocking up on compounded injectables, to what Eli Lilly's earnings call revealed about Zepbound QuickPens, refill rules, and the long-awaited retatrutide timeline, this episode covers it all. Dave also unpacks FDA enforcement signals, the escalating tension between Big Pharma and compounders, the Hims & Hers controversy, and what recent lawsuits and Super Bowl ads tell us about where obesity treatment is headed next. Clear context, real-world implications, and what patients should be discussing with their doctors right now.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

Em uma votação que uniu praticamente todos os partidos, do PL ao PT, a Câmara dos Deputados aprovou a urgência para o Projeto de Lei que declara os medicamentos Mounjaro e Zepbound (à base de tirzepatida) como de "interesse público".A medida, proposta pelo deputado Dr. Mário Heringer (PDT-MG), abre caminho para o licenciamento compulsório — a famosa quebra de patente — visando baratear o acesso às canetas emagrecedoras, consideradas por muitos parlamentares uma ferramenta essencial de saúde pública contra a obesidade.Meio-Dia em Brasília traz as principais notícias e análises da política nacional direto   de Brasília.     Com apresentação de José Inácio Pilar e Wilson Lima, o programa aborda os temas mais quentes do cenário político e econômico do Brasil.     Com um olhar atento sobre política, notícias e economia, mantém o público bem informado.   Transmissão ao vivo de segunda a sexta-feira às 12h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br 

  This week has been heavy. While there's been a desire to focus on many things, planning food and movement simply hasn't felt possible — and that's been part of the reality. Ironically, the intention behind recording these six weeks was to build momentum and gently shift habits. But grief has its own pace, and this week made that very clear. The weight of it is real, and it doesn't follow plans. Rather than investing in stories about how this period should feel or what's expected, I've chosen to tell myself a different story about the grief I'm experiencing. Not because it removes the pain — but because sitting under a dark cloud and letting it take over doesn't feel like a choice I'm willing to make. In this episode, I share how I'm simplifying food by ordering online to make quick, nourishing meals easier, and why that matters right now. I also talk about turning to art as a release — christening the easel and allowing creativity to hold some of what words can't. I reflect honestly on noticing patterns of addictive behaviour, how the idea of wine began to feel like comfort, and why I made the decision to keep no wine in the house during this time. This episode is about gentleness, awareness, and choosing care — even when everything feels heavy. In this episode: Navigating food when energy and motivation are low Letting go of expectations around grief Creating simple systems to support nourishment Using art as an emotional outlet Recognising and responding to addictive patterns Making conscious choices during a vulnerable week  

SPONSORS: - Sponsored by Pepsi. Go try Pepsi Zero Sugar today. Let Your Taste Decide. - Protect your family with life insurance from Ethos. Get up to $3 million in coverage in as little as 10 minutes at https://ethos.com/BEARS. Application times may vary. Rates may vary. - Get 10% off your first month of BlueChew Gold with code BEARS at https://bluechew.com - Sign up for your one-dollar-per-month trial and start selling today at https://shopify.com/bears - Sponsored by BetterHelp. BetterHelp makes it easy to get matched online with a qualified therapist. Sign up and get 10% off at https://BetterHelp.com/bears - Head to https://factormeals.com/bears50off and use code bears50off to get 50 percent off and free breakfast for a year. - Get up to 55% off at https://Babbel.com/BEARS. This week on Two Bears, One Cave, Tom Segura and Bert Kreischer spiral gloriously through brand loyalty, fast-food hot takes, donuts, Super Bowl commercials, health scares, and the kind of brutally honest conversations only best friends can have. The Bears break down why Pepsi Zero Sugar might actually be better than Coke Zero, debate McDonald's fries vs. literally everyone else, and revisit classic brand wars like Burger King vs. McDonald's and Dunkin' vs. Krispy Kreme. From Blooming Onion horror stories to why you should never order seafood at a steakhouse, this episode is packed with food takes that will absolutely start arguments. Bert also opens up about his recent blood clot scare, panic attacks, medications, and how the experience completely shifted his perspective on health, mortality, and gratitude. The guys also talk sleep apnea machines, Benadryl addictions, Mounjaro side effects, testosterone confusion, and why medical advice somehow never agrees ever. Plus: donut shop conspiracies in Los Angeles, Cambodian vs. Vietnamese sandwich excellence, Krispy Kreme's wild history, Instagram's “fatties eating” algorithm, tracking down Ari Shaffir in the jungle, and why the 2 Bears 5K might literally save lives. 2 Bears, 1 Cave Ep. 324 https://tomsegura.com/tour https://www.bertbertbert.com/tour https://store.ymhstudios.com Chapters 00:00:00 - Intro 00:00:06 - Brand Wars 00:07:07 - Weight Loss Drugs 00:14:58 - Pepsi Challenge 00:22:40 - I Bought A Donut Shop 00:39:22 - Coin Pusher 00:40:54 - 2 Bears 5K Is Back! 00:45:13 - Bert's Blood Clot 00:49:38 - Where In The World Is Ari Shaffir? 00:54:39 - Black Appreciation 01:00:41 - Wrap Up Learn more about your ad choices. Visit megaphone.fm/adchoices

Grâce à une fiscalité avantageuse, l'Irlande a su attirer les géants pharmaceutiques, au point d'en faire l'un des piliers de son économie. Mais Donald Trump brandit désormais la menace de droits de douane, pour pousser ces entreprises à relocaliser aux Etats-Unis. Or, les médicaments représentent près de la moitié des exportations irlandaises, avec les États-Unis comme premier client ! En Europe, l'Irlande serait ainsi le pays le plus exposé. Près de Cork, Ringaskiddy, surnommé le « village du Viagra », retient son souffle. Reportage de Clémence Pénard. John n'avait que 22 ans quand Pfizer s'est installé à Ringaskiddy. C'était en 1969 : « Tu vois, juste là, le château d'eau ? L'espèce de champignon, là ! Ça appartient à Pfizer !  » Le succès est tel que l'entreprise s'empresse de construire deux autres usines. Si bien qu'aujourd'hui, sous les coups de 8 heures, le site devient une véritable fourmilière : « Le matin, les routes sont totalement saturées : les files de voitures s'étendent sur des kilomètres. Et c'est la même chose le soir ! Une autoroute devait être construite il y a trente ans… Bon, elle doit être terminée d'ici trois ans. On vit dans l'espoir ! » Le « Pfizer Stop » Un arrêt de bus, le « Pfizer Stop », a tout de même été créé, rien que pour les salariés qui produisent, depuis 1998, le médicament le plus tonique de la région : le viagra !  « À l'époque, on n'arrivait même pas à prononcer le nom : "Pf i zeur" ! Mais tout le monde voulait y travailler, absolument tout le monde. Les salaires étaient multipliés par quatre ! Même le fournisseur de papier toilette était devenu riche ! » Et il n'a pas fallu longtemps pour que le « village du Viagra » attire d'autres géants pharmaceutiques. Aujourd'hui, les Américains Johnson & Johnson, Thermo Fisher ou encore BioMarin profitent eux aussi du port de cet ancien village de pêcheurs, idéal pour exporter leurs médicaments !  Et à seulement 20 km de là, Lilly fabrique Mounjaro et Zepbound, deux médicaments anti-obésité, best-sellers aux États-Unis !  Ambiance à Ringaskiddy et dans les villages voisins Ainsi, dans Ringaskiddy et les villages voisins, ce sont plus de 20 000 personnes qui travaillent pour ces mastodontes, souvent de génération en génération. Audrey Buckley est élue locale du Fianna Fáil, le parti au pouvoir : « S'il arrivait quoi que ce soit à l'industrie pharmaceutique ici, ce serait tout simplement dévastateur pour toute la région. Dévastateur… Aujourd'hui, au dîner autour de la table, les mêmes questions reviennent sans cesse : est-ce que tels travaux ont démarré à l'usine? Est-ce qu'il y a de nouveaux projets ? Or, tout semble à l'arrêt. C'est une énorme source d'angoisse, les gens repoussent l'achat d'une voiture, l'extension de la maison, et ainsi de suite. Ils dépensent moins, c'est sûr, donc on voit déjà des effets ! »  Économiste à l'université de Cork, Eleanor Doyle voit aussi un ralentissement du secteur, mais tente tout de même de rassurer : « Pour les usines pharmaceutiques, les délais pour obtenir les autorisations de construction sont si longs, qu'à moyen terme, une délocalisation est peu envisageable ! » Pour l'instant, l'Irlande profite d'un répit, l'administration américaine semblant se concentrer sur d'autres régions du monde.

Send us a textUniversity of Maryland School of Medicine (UMSOM) associate professor Sarah M. Kattakuzhy, MD, joins “The UMB Pulse” this month to talk about her research exploring whether semaglutide (a GLP-1 medication widely used for diabetes and weight management) could help reduce cravings and improve outcomes for people with stimulant use disorder.Kattakuzhy, who is also the co-director of the Kahlert Institute for Addiction Medicine at UMSOM, describes the design of the STAC Study, which is evaluating the safety and tolerability of semaglutide in people with cocaine use disorder, including participants with and without HIV, while also tracking secondary outcomes such as changes in drug use and cravings.She also discusses why stimulant use disorders, including cocaine and methamphetamine use disorder, have been especially challenging to treat, and how her work through the University of Maryland, Baltimore community-based research partnerships aims to expand treatment options and reduce stigma around substance use disorders.To learn more about this trial or for referrals, contact Dr. Kattakuzhy at skattakuzhy@ihv.umaryland.edu.00:00 Introduction to Addiction and New Research00:40 Meet Dr. Sarah Kattakuzhy01:45 A Day in the Life of Dr. Kattakuzhy03:57 The Journey to Addiction Research07:40 Exploring Semaglutides for Addiction Treatment12:34 Details of the Clinical Trial20:29 Challenges and Hopes in Addiction Treatment24:31 Collaborations and Future Directions27:39 Final Thoughts and Takeaways32:13 Post-Interview InsightsListen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

Send us a textThis week on On The Pen: The Weekly Dose, Dave breaks down one of the most consequential Eli Lilly earnings calls to date. We dive into major updates on retatrutide, new Phase 3 timelines, and why Lilly is positioning next-generation GLP-1 and GIP therapies far beyond obesity, including osteoarthritis, sleep apnea, addiction, and mental health. From manufacturing scale and Medicare access to brand-new molecules like bernipotide and amylin-based therapies, this episode explores what the future of incretin medicine could really look like for patients.Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Send a Text Message. Please include your name and email so we can answer you! Please note, this does not subscribe you to our email list, it's just to answer if you have a questions for us. What happens when the medication that's finally helping you is no longer affordable?If you've had success on Mounjaro or Zepbound but need to switch to a more affordable option like Ozempic for maintenance, you're probably wondering: will this actually work? And if semaglutide didn't help you before, the idea of going back can feel risky, especially when you're worried about regaining weight, increased food noise, or losing the progress you've worked so hard for.In this episode, I break down when switching medications for cost makes sense, when it's likely to backfire, and what your options are if semaglutide is the only affordable option. Referenceshttps://www.orchardpond.com/The 30/30 Program (Sept 2026 registration now open)Audio Stamps01:08 - Update on Dr. Rentea's retreat planning, plus her new favorite granola discovery.05:03 -  Listener question: Switching from Mounjaro to Ozempic for long-term maintenance due to cost.05:59 - When it makes sense to switch medications for affordability (and when it doesn't).08:03 -  If semaglutide is your only option: combining GLP-1s with oral medications.10:48 - Oral (daily) Wegovy vs injections: does steadier dosing actually help?11:40 - Why no medication is perfect and working with the right clinician is key.12:58 - The real reason behind this work: preventing disease, not chasing a number on the scale.14:05 - September 30/30 program update: early registration + monthly Q&A access.All of the information on this podcast is for general informational purposes only. Please talk to your physician and medical team about what is right for you. No medical advice is being on this podcast. If you live in Indiana or Illinois and want to work with doctor Matthea Rentea, you can find out more on www.RenteaClinic.com Not Sure Where to Start With the Podcast? I've Got You.Get my free Podcast Roadmap—a simple guide to help you find the episodes that matter most to your journey. Whether you're on GLP-1s, navigating plateaus, or just starting out, there's something here for you.Support the show

Are today's diabetes medications actually treating the disease, or just managing symptoms? In this episode, renowned diabetes educator Gary Scheiner breaks down the fast-growing world of GLP-1 drugs like Ozempic and Mounjaro – explaining what they do, who they're for, and why they're so effective… As the owner and clinical director of Integrated Diabetes Services, Gary has devoted his career to improving the lives of people with insulin-dependent diabetes. Living with type 1 diabetes since 1985, he is an award-winning Certified Diabetes Care and Education Specialist, a master's-level exercise physiologist, and was named 2014 Diabetes Educator of the Year by the American Association of Diabetes Educators. He's also the author of several foundational books, including Think Like a Pancreas, Get Control of Your Blood Sugar, and The Ultimate Guide to Accurate Carb Counting, and is a frequent speaker at national and international diabetes conferences. Jump in now to find out: The importance of finding a healthy balance when managing diabetes. What makes GLP-1 medications unique.  How diabetes impacts food digestion. What elevated glucose levels do to the rest of the body. To keep up with Gary and his work, follow him on LinkedIn!